Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy for Stress Urinary Incontinence

Cytori Therapeutics (NASDAQ:CYTX) announced that full enrollment has been reached in the ADRESU investigator-initiated clinical trial of Cytori Cell Therapy for men with stress urinary incontinence as a complication of prostate intervention.  A total of 45 patients, all treated in Japan, were enrolled in this potential approval trial.

As quoted in the press release:

The primary endpoint for the ADRESU trial is the percentage of patients who experience greater than 50% reduction in urinary leakage volume from baseline (as measured by the weight of unintended urinary leakage over 24 hours) at 52 weeks after treatment. A number of other key secondary endpoints are also being assessed. If the primary endpoint is successfully achieved, the data may be used to seek approval of ECCI-50 for this indication.

Click here to read the full press release.